Previous 10 | Next 10 |
At a time when many businesses have been impacted by the financial consequences of the coronavirus pandemic, Repligen (NASDAQ: RGEN) continues to hum along. The bioprocess engineering leader reported record quarterly revenue and profitability in the Q2 2020, and management raised full-year 2...
Repligen Corporation (RGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participants ...
Repligen (NASDAQ: RGEN ) : Q2 Non-GAAP EPS of $0.42; GAAP EPS of $0.30 beats by $0.14 . More news on: Repligen Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Reports record quarterly revenue of $87.5 million Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth Completes acquisition of silicone molding and tubing manufa...
WALTHAM, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2020 financial results on Thursday, July 30, 2020. The Company will issue a press release before the market opens and will host a conference c...
Shares of Repligen (NASDAQ: RGEN) rose nearly 34% in the first half of 2020, according to data provided by S&P Global Market Intelligence . That easily bested the 4% decline of the S&P 500 in what has been a volatile six months for investors. The bioprocess leader designs and man...
Heating, ventilation, and air conditioning (HVAC) company AAON (NASDAQ: AAON) , bioprocess engineering products company Repligen (NASDAQ: RGEN) , and machine vision company Cognex (NASDAQ: CGNX) are vastly different companies. But they have one thing in common: They're all highly attra...
Repligen ( RGEN +0.1% ) to acquire Albany based Engineered Molding Technology (“EMT”), a manufacturer of single-use silicone assemblies and components used in the manufacturing of biologic drugs. More news on: Repligen Corporation, Healthcare stocks news, Merger...
WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into an agreement to acquire Albany, New York based Engineered Molding Technology (“EMT...
WALTHAM, Mass., June 15, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role over 23 years of leadership experience acro...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...